PRQ620 is a highly potent and selective mTORC1/2 inhibitor, shows anti-tumor effects in vitro and in vivo.

(+)-Usniacin, a naturally occurring dibenzofuran derivative isolated and purified from the Usnea diffracta Vain. with antitumoral, antiviral, antibiotic, acaricidal, antipyretic, analgesic, antioxidative and anti-inflammatory activities.

CC-115 is an inhibitor of mTOR and DNA-PK with IC50 of 21 and 13 nM respectively.

ACAT inhibitor

Camonsertib（RP-3500）是一种新型、强效且选择性的ATR抑制剂。Camonsertib具有治疗多种癌症（如具有DNA修复缺陷的肿瘤）的潜力。

GDC-0349 is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, showing > 700-fold selectivity over PI3Kα and other 266 kinases.

CC-223 is a potent mTOR kinase inhibitor (IC50=16 nM), with > 150-fold sensitivity over the related lipid kinase PI3Kα (IC50=4 μM).

MHY1485是一种有效的、细胞可渗透的mTOR激活剂，靶向mTOR的ATP域，并通过抑制自噬体与溶酶体的融合来抑制自噬。

KU-0063794 is a selective inhibitor of mammalian target of rapamycin (mTOR) (IC50 ~10 nM for mTORC1 and mTORC2 respectively) with no effect on PI3Ks.

RapaLink-1 is the third-generation mTOR inhibitor exploiting the unique juxtaposition of two drug (first- and second-generation mTOR kinase inhibitors) –binding pockets to create a bivalent interaction that allows inhibition of the mutants which has resistance to the previous TORKi (mTOR kinase inhibitors).

Sapanisertib (INK-128; MLN0128; TAK-228) 是一种口服可用的ATP依赖性mTOR1/2抑制剂，对mTOR激酶的IC50为1 nM。

AZD-8055是一种有效、选择性且口服可用的ATP竞争性mTOR激酶抑制剂，IC50为0.8 nM，抑制mTORC1和mTORC2。

Everolimus (RAD001)是雷帕霉素的衍生物，是一种强效、选择性、口服活性的 mTOR1 抑制剂。它与 FKBP-12 结合形成免疫抑制复合物，抑制肿瘤细胞增殖，诱导细胞凋亡和自噬，表现出强效的免疫抑制和抗癌活性。